BLACKROCK CAPITAL ALLOC TR (BCAT) Fundamental Analysis & Valuation

NYSE:BCAT • US09260U1097

15.15 USD
+0.08 (+0.53%)
At close: Mar 9, 2026
15.23 USD
+0.08 (+0.53%)
After Hours: 3/9/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis News

This BCAT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BCAT. BCAT was compared to 0 industry peers in the Unkown industry. The financial health of BCAT is average, but there are quite some concerns on its profitability. BCAT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. BCAT Profitability Analysis

1.1 Basic Checks

  • BCAT had positive earnings in the past year.
  • In the past year BCAT had a positive cash flow from operations.
  • BCAT had positive earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: BCAT reported negative operating cash flow in multiple years.
BCAT Yearly Net Income VS EBIT VS OCF VS FCFBCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -1B -2B

1.2 Ratios

Industry RankSector Rank
ROA 8.47%
ROE 9.62%
ROIC 2.18%
ROA(3y)1.93%
ROA(5y)3.01%
ROE(3y)1.54%
ROE(5y)3.06%
ROIC(3y)2.43%
ROIC(5y)1.81%
BCAT Yearly ROA, ROE, ROICBCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 5 -5 10 -10 -15

1.3 Margins

  • BCAT's Profit Margin has improved in the last couple of years.
  • BCAT's Operating Margin has improved in the last couple of years.
  • BCAT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 66.67%
PM (TTM) 228.99%
GM 69.57%
OM growth 3Y2.53%
OM growth 5YN/A
PM growth 3Y26.3%
PM growth 5YN/A
GM growth 3Y3.11%
GM growth 5YN/A
BCAT Yearly Profit, Operating, Gross MarginsBCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 500 1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BCAT Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for BCAT has been reduced compared to 1 year ago.
  • BCAT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCAT Yearly Shares OutstandingBCAT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
BCAT Yearly Total Debt VS Total AssetsBCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 4.18 indicates that BCAT is not in any danger for bankruptcy at the moment.
  • BCAT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.18
ROIC/WACCN/A
WACCN/A
BCAT Yearly LT Debt VS Equity VS FCFBCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 1B -1B 2B -2B

2.3 Liquidity

  • A Current Ratio of 0.18 indicates that BCAT may have some problems paying its short term obligations.
  • BCAT has a Quick Ratio of 0.18. This is a bad value and indicates that BCAT is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.18
Quick Ratio 0.18
BCAT Yearly Current Assets VS Current LiabilitesBCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BCAT Growth Analysis

3.1 Past

  • BCAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.05%.
  • BCAT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.50% yearly.
  • Looking at the last year, BCAT shows a very negative growth in Revenue. The Revenue has decreased by -15.37% in the last year.
  • BCAT shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.40% yearly.
EPS 1Y (TTM)-22.05%
EPS 3Y19.5%
EPS 5YN/A
EPS Q2Q%-25.2%
Revenue 1Y (TTM)-15.37%
Revenue growth 3Y-7.4%
Revenue growth 5YN/A
Sales Q2Q%-21.43%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAT Yearly Revenue VS EstimatesBCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

Find the best growth stocksShow best growing peers

1

4. BCAT Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.97, the valuation of BCAT can be described as very reasonable.
  • When comparing the Price/Earnings ratio of BCAT to the average of the S&P500 Index (26.46), we can say BCAT is valued rather cheaply.
Industry RankSector Rank
PE 9.97
Fwd PE N/A
BCAT Price Earnings VS Forward Price EarningsBCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 3.86
EV/EBITDA N/A
BCAT Per share dataBCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. BCAT Dividend Analysis

5.1 Amount

  • BCAT has a Yearly Dividend Yield of 19.19%, which is a nice return.
  • Compared to an average S&P500 Dividend Yield of 1.82, BCAT pays a better dividend.
Industry RankSector Rank
Dividend Yield 19.19%

5.2 History

  • BCAT has been paying a dividend for over 5 years, so it has already some track record.
  • BCAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years4
BCAT Yearly Dividends per shareBCAT Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • 228.48% of the earnings are spent on dividend by BCAT. This is not a sustainable payout ratio.
DP228.48%
EPS Next 2YN/A
EPS Next 3YN/A
BCAT Yearly Income VS Free CF VS DividendBCAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 0 -1B -2B
BCAT Dividend Payout.BCAT Dividend Payout, showing the Payout Ratio.BCAT Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BCAT Fundamentals: All Metrics, Ratios and Statistics

BLACKROCK CAPITAL ALLOC TR

NYSE:BCAT (3/9/2026, 8:04:00 PM)

After market: 15.23 +0.08 (+0.53%)

15.15

+0.08 (+0.53%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-02
Earnings (Next)N/A
Inst Owners20.31%
Inst Owner Change4.81%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.59B
Revenue(TTM)69.00M
Net Income(TTM)158.00M
Analysts0
Price TargetN/A
Short Float %0.96%
Short Ratio1.32
Dividend
Industry RankSector Rank
Dividend Yield 19.19%
Yearly Dividend2.65
Dividend Growth(5Y)N/A
DP228.48%
Div Incr Years2
Div Non Decr Years4
Ex-Date06-15
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 9.97
Fwd PE N/A
P/S 23.01
P/FCF 3.86
P/OCF 3.86
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)1.52
EY10.03%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)3.92
FCFY25.89%
OCF(TTM)3.92
OCFY25.89%
SpS0.66
BVpS15.67
TBVpS15.67
PEG (NY)N/A
PEG (5Y)N/A
Graham Number23.15
Profitability
Industry RankSector Rank
ROA 8.47%
ROE 9.62%
ROCE 2.76%
ROIC 2.18%
ROICexc 2.18%
ROICexgc 2.18%
OM 66.67%
PM (TTM) 228.99%
GM 69.57%
FCFM 595.65%
ROA(3y)1.93%
ROA(5y)3.01%
ROE(3y)1.54%
ROE(5y)3.06%
ROIC(3y)2.43%
ROIC(5y)1.81%
ROICexc(3y)2.43%
ROICexc(5y)1.81%
ROICexgc(3y)2.46%
ROICexgc(5y)1.84%
ROCE(3y)3.07%
ROCE(5y)2.33%
ROICexgc growth 3Y13.87%
ROICexgc growth 5YN/A
ROICexc growth 3Y14.48%
ROICexc growth 5YN/A
OM growth 3Y2.53%
OM growth 5YN/A
PM growth 3Y26.3%
PM growth 5YN/A
GM growth 3Y3.11%
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 260.13%
Current Ratio 0.18
Quick Ratio 0.18
Altman-Z 4.18
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.05%
EPS 3Y19.5%
EPS 5YN/A
EPS Q2Q%-25.2%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.37%
Revenue growth 3Y-7.4%
Revenue growth 5YN/A
Sales Q2Q%-21.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.86%
EBIT growth 3Y-5.06%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.48%
OCF growth 3YN/A
OCF growth 5YN/A

BLACKROCK CAPITAL ALLOC TR / BCAT FAQ

What is the ChartMill fundamental rating of BLACKROCK CAPITAL ALLOC TR (BCAT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCAT.


Can you provide the valuation status for BLACKROCK CAPITAL ALLOC TR?

ChartMill assigns a valuation rating of 1 / 10 to BLACKROCK CAPITAL ALLOC TR (BCAT). This can be considered as Overvalued.


Can you provide the profitability details for BLACKROCK CAPITAL ALLOC TR?

BLACKROCK CAPITAL ALLOC TR (BCAT) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for BCAT stock?

The Price/Earnings (PE) ratio for BLACKROCK CAPITAL ALLOC TR (BCAT) is 9.97 and the Price/Book (PB) ratio is 0.97.


What is the financial health of BLACKROCK CAPITAL ALLOC TR (BCAT) stock?

The financial health rating of BLACKROCK CAPITAL ALLOC TR (BCAT) is 5 / 10.